Genflow Targets 25% Global NAFLD Prevalence with SIRT6 Patent Progression

For healthcare providers and hepatology specialists, the lack of approved NASH therapies remains a critical gap. Genflow's pursuit of a SIRT6-based approach could address the metabolic root of liver disease, with US patent publication signaling a serious commitment to clinical translation.

Genflow Biosciences Plc, a London-listed longevity research company, has announced a significant advancement in its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) published the Company's patent application US 2026/0199524 A1, entitled "Variants of Sirtuin 6 for the Treatment of Non-Alcoholic Fatty Liver Disease." The application covers the use of Genflow's centenarian-derived SIRT6 variant (N308K/A313S) in the prevention and/or treatment of non-alcoholic fatty liver disease (NAFLD), including its more severe form, non-alcoholic steatohepatitis (NASH). This publication, while procedural and not a grant, marks a key milestone in establishing an exclusive commercial position for what the company claims is a first-in-class therapeutic candidate targeting metabolic and aging-related liver disease.

“

Genflow Biosciences Plc, a London-listed longevity research company, has announced a significant advancement in its intellectual property portfolio.

The announcement, made under the UK's Market Abuse Regulation, underscores the material significance of the patent update. Genflow's strategy extends beyond a single filing. CEO Dr. Eric Leire emphasized a layered intellectual property approach spanning two principal SIRT6 patent families: a foundational SIRT6c family, exclusively licensed to Genflow, which seeks broad protection for the variant itself, and a company-owned MASH family that adds indication-specific claims. The newly published US application falls within the MASH family. Beyond these, Genflow has disclosed filings related to delivery mechanisms and muscular-disease applications, bringing the total number of distinct patent families to four. This multi-family, multi-jurisdiction strategy is designed to create a dense thicket of protection around the SIRT6 variant, deterring competitors and enhancing the asset's valuation in the eyes of investors and potential partners.

From a scientific perspective, the SIRT6 variant in question is not a synthetic construct but a naturally occurring double-mutation (N308K/A313S) identified in centenarians, who are known for healthy aging and longevity. The variant is believed to confer enhanced sirtuin activity, which plays a role in DNA repair, metabolism, and inflammation. By targeting NAFLD/NASH—a global health problem affecting roughly one in four adults with no approved pharmacotherapy—Genflow is entering a high-value therapeutic area. The application names Dr. Manlio Vinciguerra, a leading researcher in sirtuin biology, and Dr. Leire as inventors, a combination that blends scientific credibility with executive control over the IP.

The legal implications are substantial. The publication starts the clock on several procedural milestones under US patent law: the application will now undergo substantive examination, during which claims may be narrowed, rejected, or allowed. A granted patent would give Genflow the right to exclude others from making, using, or selling the claimed SIRT6-based therapy in the United States for 20 years from the priority date. Moreover, the European progress mentioned by the company suggests parallel filings are underway, which could lead to pan-European protection. For competitors in the longevity and NASH spaces—ranging from small biotechs to large pharma—this filing serves as a clear notice of Genflow's ambitions and could trigger patent watch, opposition, or design-around efforts.